Overview
- The Isaac device estimates blood glucose from exhaled volatile organic compounds, notably acetone.
- PreEvnt publicly demonstrated the quarter-sized pendant at CES 2026, with readings logged to a companion smartphone app.
- Reporters performed brief spot checks by breathing into the device, which is designed for momentary tests rather than continuous monitoring.
- Human trials at Indiana University began with adolescents with type 1 diabetes and plan expansion to adults with type 2 diabetes to compare results with standard measures.
- The company says it is preparing a de novo submission and educating the FDA during review, while miniaturization for future wearables remains a reported challenge.